RT Journal Article
SR Electronic
T1 Blood-based screening for HPV-associated cancers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.04.24300841
DO 10.1101/2024.01.04.24300841
A1 Das, Dipon
A1 Hirayama, Shun
A1 Aye, Ling
A1 Bryan, Michael E.
A1 Naegele, Saskia
A1 Zhao, Brian
A1 Efthymiou, Vasileios
A1 Mendel, Julia
A1 Fisch, Adam S.
A1 Kröller, Lea
A1 Michels, Birgitta E.
A1 Waterboer, Tim
A1 Richmon, Jeremy D.
A1 Adalsteinsson, Viktor
A1 Lawrence, Michael S.
A1 Crowson, Matthew G.
A1 Iafrate, A. John
A1 Faden, Daniel L.
YR 2024
UL http://medrxiv.org/content/early/2024/02/02/2024.01.04.24300841.abstract
AB Background HPV-associated oropharyngeal cancer (HPV+OPSCC) is the most common HPV-associated cancer in the United States yet unlike cervical cancer lacks a screening test. HPV+OPSCCs are presumed to start developing 10-15 years prior to clinical diagnosis. Circulating tumor HPV DNA (ctHPVDNA) is a sensitive and specific biomarker for HPV+OPSCC. Taken together, blood-based screening for HPV+OPSCC may be feasible years prior to diagnosis.Methods We developed an HPV whole genome sequencing assay, HPV-DeepSeek, with 99% sensitivity and specificity at clinical diagnosis. 28 plasma samples from HPV+OPSCC patients collected 1.3-10.8 years prior to diagnosis along with 1:1 age and gender-matched controls were run on HPV-DeepSeek and an HPV serology assay.Results 22/28 (79%) of cases and 0/28 controls screened positive for HPV+OPSCC with 100% detection within four years of diagnosis and a maximum lead time of 7.8 years. We next applied a machine learning model classifying 27/28 cases (96%) with 100% detection within 10 years. Plasma-based PIK3CA gene mutations, viral genome integration events and HPV serology were used to orthogonally validate cancer detection with 68% (19/28) of the cohort having multiple cancer signals detected. Molecular fingerprinting of HPV genomes was performed across patients demonstrating that each viral genome was unique, ruling out contamination. In patients with tumor blocks from diagnosis (15/28), molecular fingerprinting was performed within patients confirming the same viral genome across time.Conclusions We demonstrate accurate blood-based detection of HPV-associated cancers with lead times up to 10 years before clinical cancer diagnosis and in doing so, highlight the enormous potential of ctDNA-based cancer screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDaniel Faden receives salary support from NIH K23, R03 and R21 grantsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Dana Farber/ Harvard Cancer Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript